NCT03736863View on ClinicalTrials.gov

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

June 20, 2021

Study Completion Date

December 30, 2025

Conditions
Esophageal Cancer
Interventions
DRUG

Apatinib+ SHR-1210（Camrelizumab）

Apatinib 250mg, q.d.po+SHR-1210（Camrelizumab）200 mg，Intravenous injection，q2W

DRUG

Apatinib+ SHR-1316（Adebrelimab）

Apatinib 250mg, q.d.po+SHR-1316（Adebrelimab） 1200 mg，Intravenous injection，q2W

DRUG

SHR-1316（Adebrelimab）+SHR-A2009

SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,

Trial Locations (1)

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER